Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.

Chatterjee S, Patel HK, Sansgiry SS.

Pharm Pract (Granada). 2012 Oct;10(4):194-8. Epub 2012 Dec 31.

3.

Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.

Pharmaceut Med. 2008 Mar 1;22(2). doi: 10.1007/BF03256691.

4.

FDA actions against health economic promotions, 2002-2011.

Neumann PJ, Bliss SK.

Value Health. 2012 Sep-Oct;15(6):948-53. doi: 10.1016/j.jval.2012.05.002. Epub 2012 Jun 15.

5.

A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.

Symonds T, Hackford C, Abraham L.

Value Health. 2014 Jun;17(4):433-7. doi: 10.1016/j.jval.2014.03.1718.

6.

Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.

Kim H.

Int J Health Policy Manag. 2015 Aug 25;4(12):813-21. doi: 10.15171/ijhpm.2015.157.

7.

Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.

Kannan S, Gowri S, Tyagi V, Kohli S, Jain R, Kapil P, Bhardwaj A.

Int J Risk Saf Med. 2015;27(2):77-83. doi: 10.3233/JRS-150644.

PMID:
26410010
8.

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.

Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.

BMC Health Serv Res. 2013 Jan 22;13:27. doi: 10.1186/1472-6963-13-27.

9.
11.

Single Cigarette Sales: State Differences in FDA Advertising and Labeling Violations, 2014, United States.

Baker HM, Lee JG, Ranney LM, Goldstein AO.

Nicotine Tob Res. 2016 Feb;18(2):221-6. doi: 10.1093/ntr/ntv053. Epub 2015 Mar 5.

12.

Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.

Shetty YC, Saiyed AA.

J Med Ethics. 2015 May;41(5):398-403. doi: 10.1136/medethics-2013-101829. Epub 2014 Jun 25.

PMID:
24965716
13.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

14.

Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.

Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, Kumar R.

J Pharm Pharm Sci. 2006;9(1):50-9.

15.

Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.

Tyrawski J, DeAndrea DC.

J Med Internet Res. 2015 Jun 1;17(6):e130. doi: 10.2196/jmir.4357.

16.
17.

[Early achievements of the Danish pharmaceutical industry--8. Lundbeck].

Grevsen JV, Kirkegaard H, Kruse E, Kruse PR.

Theriaca. 2016;(43):9-61. Danish.

PMID:
27491172
20.

Supplemental Content

Support Center